Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel.
| Revenue (Most Recent Fiscal Year) | $160.95M |
| Net Income (Most Recent Fiscal Year) | $14.46M |
| PE Ratio (Current Year Earnings Estimate) | 18.64 |
| PE Ratio (Trailing 12 Months) | 20.65 |
| PEG Ratio (Long Term Growth Estimate) | 0.75 |
| Price to Sales Ratio (Trailing 12 Months) | 2.38 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.55 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 14.28 |
| Pre-Tax Margin (Trailing 12 Months) | 11.07% |
| Net Margin (Trailing 12 Months) | 11.22% |
| Return on Equity (Trailing 12 Months) | 7.41% |
| Return on Assets (Trailing 12 Months) | 5.18% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.00 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.21 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.23 |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.52 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.13 |
| Earnings per Share (Most Recent Fiscal Year) | $0.25 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.34 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 57.51M |
| Free Float | 36.75M |
| Market Capitalization | $403.68M |
| Average Volume (Last 20 Days) | 0.05M |
| Beta (Past 60 Months) | 0.93 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 36.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 20.38% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |